Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: an exploratory analysis of real-world data

The combination of gemcitabine and cisplatin (gem/cis) with the anti-PD-L1-antibody durvalumab was recently approved as first line therapy for biliary tract cancer (BTC) based on the results of the TOPAZ-1 trial.

Saved in:

Bibliographic Details
Main Authors:	Olkus, Alexander (Author) , Tomczak, Aurelie (Author) , Berger, Anne Katrin (Author) , Rauber, Conrad (Author) , Puchas, Philip (Author) , Wehling, Cyrill (Author) , Longerich, Thomas (Author) , Mehrabi, Arianeb (Author) , Chang, De-Hua (Author) , Liermann, Jakob (Author) , Schäfer, Sophia (Author) , Pfeiffenberger, Jan (Author) , Jäger, Dirk (Author) , Michl, Patrick (Author) , Springfeld, Christoph (Author) , Dill, Michael T. (Author)
Format:	Article (Journal)
Language:	English
Published:	March 2024
In:	Targeted oncology Year: 2024, Volume: 19, Issue: 2, Pages: 213-221
ISSN:	1776-260X
DOI:	10.1007/s11523-024-01044-1
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s11523-024-01044-1
Author Notes:	Alexander Olkus, Aurelie Tomczak, Anne Katrin Berger, Conrad Rauber, Philip Puchas, Cyrill Wehling, Thomas Longerich, Arianeb Mehrabi, De-Hua Chang, Jakob Liermann, Sophia Schäfer, Jan Pfeiffenberger, Dirk Jäger, Patrick Michl, Christoph Springfeld, Michael T. Dill

Description
Summary:	The combination of gemcitabine and cisplatin (gem/cis) with the anti-PD-L1-antibody durvalumab was recently approved as first line therapy for biliary tract cancer (BTC) based on the results of the TOPAZ-1 trial.
Item Description:	Online veröffentlicht: 28. Februar 2024 Gesehen am 09.10.2024
Physical Description:	Online Resource
ISSN:	1776-260X
DOI:	10.1007/s11523-024-01044-1